[Musculoskeletal adverse effects of levofloxacin].
Rivero
M
M
Clínica Ubarmin, Elcano, Navarra.
Otermin
I
I
Pereda
A
A
Cía
M
M
Martínez
M
M
D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000139:chemically induced*; D001168:Arthritis / Q000139:chemically induced*; D001170:Arthritis, Infectious / Q000188:drug therapy / Q000601:surgery; D019645:Arthroplasty, Replacement, Knee; D000069059:Atorvastatin; D003131:Combined Modality Therapy; D003646:Debridement; D003937:Diagnosis, Differential; D004318:Doxycycline / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000188:drug therapy; D064704:Levofloxacin; D008875:Middle Aged; D015242:Ofloxacin / Q000009:adverse effects* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000139:chemically induced; D016459:Prosthesis-Related Infections / Q000188:drug therapy / Q000601:surgery; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D012086:Reoperation; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D013967:Thyroiditis, Autoimmune / Q000150:complications / Q000188:drug therapy; D013974:Thyroxine / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D064704:Levofloxacin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000069059:Atorvastatin; D015242:Ofloxacin; D004318:Doxycycline; D013974:Thyroxine; D012293:Rifampin